Soeren Mattke

Aug 7, 2024 | neurologylive.com | Soeren Mattke |Isabella Ciccone

WATCH TIME: 4 minutes"I think the blood test can truly revolutionize the diagnosis of Alzheimer disease and also the treatment monitoring."As therapies for Alzheimer disease (AD) become more available to patients, studies show a rise in patient concerns about wait times in their diagnostic journey because of the limited number of AD specialists and PET scanners.

Jul 31, 2024 | neurologylive.com | Soeren Mattke |Isabella Ciccone

As therapies become available for patients with Alzheimer disease (AD), studies show a growing concern from patients about wait times in getting diagnosis because of the limited accessible AD specialists and PET scanners.

Jul 28, 2024 | neurologylive.com | Soeren Mattke |Isabella Ciccone

WATCH TIME: 7 minutes"By combining cognitive assessments with blood tests in primary care, we can prioritize patients for specialist referrals more efficiently and reduce wait times."As treatments for patients with Alzheimer disease (AD) are becoming more available, several clinicians have raised concerns about wait times in patient’s diagnostic journey because of the limited amount of AD specialists and PET scanners.

Jun 12, 2024 | nature.com | Suzanne Schindler |Marc Suárez-Calvet |Ara Khachaturian |Michelle M. Mielke |Yan Hu |Soeren Mattke

AbstractAnti-amyloid treatments for early symptomatic Alzheimer disease have recently become clinically available in some countries, which has greatly increased the need for biomarker confirmation of amyloid pathology. Blood biomarker (BBM) tests for amyloid pathology are more acceptable, accessible and scalable than amyloid PET or cerebrospinal fluid (CSF) tests, but have highly variable levels of performance.

Apr 30, 2024 | innerself.com | Soeren Mattke |Ying Liu |James Nestor |Steven R. Gundry

Mild cognitive impairment can be an early sign of Alzheimer’s disease or other dementias. ivanastar/iStock via Getty Images PlusMild cognitive impairment – an early stage of dementia – is widely underdiagnosed in people 65 and older. That is the key takeaway of two recent studies from our team.